Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 470

1.

Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.

McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, Sharratt GP, Baxendale DM, Reddish MA, Hu MC, Stroop SD, Linden J, Fries LF, Vink PE, Dale JB.

Clin Infect Dis. 2005 Oct 15;41(8):1114-22. Epub 2005 Sep 12.

PMID:
16163629
2.

Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial.

Kotloff KL, Corretti M, Palmer K, Campbell JD, Reddish MA, Hu MC, Wasserman SS, Dale JB.

JAMA. 2004 Aug 11;292(6):709-15.

PMID:
15304468
4.

Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.

Olive C, Sun HK, Ho MF, Dyer J, Horváth A, Toth I, Good MF.

J Infect Dis. 2006 Aug 1;194(3):316-24. Epub 2006 Jun 30.

PMID:
16826479
5.

Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.

Olive C, Ho MF, Dyer J, Lincoln D, Barozzi N, Toth I, Good MF.

J Infect Dis. 2006 Jun 15;193(12):1666-76. Epub 2006 May 10.

PMID:
16703510
6.

Prospects for a group A streptococcal vaccine.

McMillan DJ, Chhatwal GS.

Curr Opin Mol Ther. 2005 Feb;7(1):11-6. Review.

PMID:
15732524
7.

Recombinant tetravalent group A streptococcal M protein vaccine.

Dale JB, Chiang EY, Lederer JW.

J Immunol. 1993 Aug 15;151(4):2188-94.

PMID:
8345202
8.

Vaccine strategies to prevent rheumatic fever.

Brandt ER, Good MF.

Immunol Res. 1999;19(1):89-103.

PMID:
10374697
9.

A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies.

Olive C, Batzloff MR, Horváth A, Wong A, Clair T, Yarwood P, Toth I, Good MF.

Infect Immun. 2002 May;70(5):2734-8.

10.

Evaluation of synthetic, M type-specific peptides as antigens in a multivalent group A streptococcal vaccine.

Bruner M, James A, Beall B, Carlone GM, Ades E, Johnson S, Guarner J, Sampson J.

Vaccine. 2003 Jun 20;21(21-22):2698-703.

PMID:
12798606
11.
12.

Immunogenicity of a 26-valent group A streptococcal vaccine.

Hu MC, Walls MA, Stroop SD, Reddish MA, Beall B, Dale JB.

Infect Immun. 2002 Apr;70(4):2171-7.

13.

New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.

Brandt ER, Sriprakash KS, Hobb RI, Hayman WA, Zeng W, Batzloff MR, Jackson DC, Good MF.

Nat Med. 2000 Apr;6(4):455-9.

PMID:
10742155
14.

Structural optimisation of a conformational epitope improves antigenicity when expressed as a recombinant fusion protein.

Georgousakis MM, Hofmann A, Batzloff MR, McMillan DJ, Sriprakash KS.

Vaccine. 2009 Nov 12;27(48):6799-806. doi: 10.1016/j.vaccine.2009.08.049. Epub 2009 Sep 1.

PMID:
19729086
16.

Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.

Olive C, Hsien K, Horváth A, Clair T, Yarwood P, Toth I, Good MF.

Vaccine. 2005 Mar 18;23(17-18):2298-303.

PMID:
15755615
17.

New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci.

Dale JB, Penfound TA, Chiang EY, Walton WJ.

Vaccine. 2011 Oct 26;29(46):8175-8. doi: 10.1016/j.vaccine.2011.09.005. Epub 2011 Sep 13.

18.

Immune response against M protein-conserved region peptides from prevalent group A Streptococcus in a North Indian population.

Gupta VK, Sekhar S, Dhanda V, Toor D, Kumar R, Chakraborti A.

J Microbiol Immunol Infect. 2016 Jun;49(3):352-8. doi: 10.1016/j.jmii.2014.05.008. Epub 2014 Jul 30.

19.
20.

Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?

Smeesters PR, McMillan DJ, Sriprakash KS, Georgousakis MM.

Expert Rev Vaccines. 2009 Dec;8(12):1705-20. doi: 10.1586/erv.09.133. Review.

PMID:
19905872

Supplemental Content

Support Center